|Articles|December 6, 2017
COMPASS Pathways Contracts with Worldwide Clinical Trials as its CRO for its First Large-scale Controlled Trials
Advertisement
COMPASS Pathways has contracted with Worldwide Clinical Trials as its CRO for its first ever large-scale randomized, controlled trials, covering 400 patients with treatment-resistant depression in eight countries. The trial will begin in the first quarter of 2018 and is planned to include clinical sites in Czech Republic, Finland, Germany, the Netherlands, Norway, Portugal, Spain and the UK.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
2
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
3
Generative AI Transforms Clinical Study Report Development
4
Everything to Know About FDA’s Push Towards Radical Transparency in 2025
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
